On March 31, NCI officially renewed the University of Colorado Cancer Center’s “comprehensive” designation with a strong rating, the best ever received at the CU Cancer Center.
The Cancer Care Is Different Coalition announced its support for the California Cancer Care Equity Act (SB 987), which would remove regulatory barriers that disproportionately prevent Californians in underserved communities from accessing optimal cancer care for complex cancer diagnoses.
The American Society for Radiation Oncology Board of Directors Chair Laura A. Dawson released the following statement in response to the Centers for Medicare and Medicaid Services’ decision to delay the start of the Radiation Oncology Alternative Payment Model:
The Society for Immunotherapy of Cancer is offering nine fellowships and Technology Awards, totaling $680,000 in funding. These are available to SITC members.
The PROTEUS Consortium (Patient-Reported Outcomes Tools: Engaging Users & Stakeholders) and Pfizer Global Medical Grants are collaborating to offer a grant funding opportunity to support the use of patient-reported outcome measures in clinical practice to improve the monitoring and management of patients with cancer.
African-American adult patients are more likely than white patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center.
Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.
A retrospective, observational study sponsored by G1 Therapeutics described the burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer. The study also described patient outcomes from 21 patients receiving Cosela (trilaciclib) prior to chemotherapy.
FDA approved Yescarta (axicabtagene ciloleucel) for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma.
City of Hope has evaluated Curate Biosciences’ Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR T-cell immunotherapy, the company said.
